Today we are in endless “informational” session, chaired by John Simpson from the BBC, and featuring big broadcasters from India (Zee Network), and Brazil (TV Globo), ABN Holdings Ltd (ABN) (A company headquartered England, about) and the Caribbean Communications Network Limited. Continue Reading
I spent a bit of time to look at the contributions from selected drug and medical device Political Action Committees (PACs) to the 28 House Democrats who voted for fast track on June 18, 2015. Continue Reading
We just received a reply from a September 17, 2013 FOIA request KEI filed with USTR, asking for correspondence involving General Electric’s efforts to block the WIPO Treaty for the Blind. USTR provided 24 pages of documents, available here:
Following the Friday vote in the House of Representatives which effectively blocked movement (for now) on the Trade Promotion Authority, and more generally, slowed down the TransPacific Partnership (TPP) negotiations, I was contacted by Dr. Harvey Bale, the well known former Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). In an exchange on Facebook, Dr. Bale took favorable note of the outcome on fast track, and described the vote against fast track as “A very good day, Indeed.” I asked Dr. Continue Reading
I have written an article for Medium, titled: TPP, designed to make medicine more expensive, reforms more difficult. (Link here)
Continue Reading
(More KEI RCEP leaks here: /rcep)
Last week, KEI published the October 3, 2014 Korea proposals for the RCEP IP Chapter (https://www.keionline.org/node/2239), and earlier we published a Japan proposal for the RCEP IP Chapter (/node/2173)
Today we are publishing two new proposals for the RCEP IP Chapter, the proposals by
The US Copyright Office has proposed limitations on damages and injunctions, when “orphan” copyrighted works are infringed. Continue Reading
The TPP, following a plethora of other trade agreements involving the United States, the European Union and Japan as trading partners, seeks to expand and extend drug monopolies, by requiring lower standards for the grant of patents, extensions of patent terms, exclusive rights in test data, among other measures. These proposals and polices are designed to have the predictable effect of making drug prices higher.
Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34
My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.
I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.
We have suggestions for some changes in the discussion, to move things forward.